BREAST CANCER

Research shows that tamoxifen treatment may lead to problems down the road in patients with primary breast cancer.

During a press briefing ahead of the 2021 San Antonio Breast Cancer Symposium, results from the phase 3 EMERALD trial were presented.

Imaging mass cytometry at the single-cell level may be a promising response prediction tool for immunotherapy in early triple-negative breast cancer.

In an epidemiological study, a 24-month lymphedema rate of 39.4% was the highest incidence of lymphedema observed among Black women.

A pooled analysis of results from the randomized phase 2 SAFIR02_BREAST and SAFIR-PI3K trials show promise for the use of multigene sequencing to select targeted therapy for metastatic breast cancer.

Findings from the phase 3 PADA-1 trial reveal promising progression-free survival results when treatment with fulvestrant/palbociclib follows treatment with an aromatase inhibitor plus palbociclib in a metastatic breast cancer subgroup.

Evanthia Roussos Torres, MD, PhD, discusses the follow-up research related to the phase 1 study of entinostat administered in combination with nivolumab and ipilimumab for the treatment of locally advanced, metastatic, unresectable, or HER2-negative breast cancer.

Findings from the phase 3 OlympiA led to the filing of a supplemental new drug application for olaparib as adjuvant treatment of BRCA-mutated HER2-negative high-risk early breast cancer.

The TROPION-Breast01 study aims to enroll 700 patients to determine the safety and efficacy of datopotamab deruxtecan in patients with HR-positive, HER2-negative breast cancer.

Evanthia Roussos Torres, MD, PhD, discusses the phase 1 study of the efficacy of entinostat administered in combination with nivolumab and ipilimumab for the treatment of locally advanced, metastatic, unresectable, or HER2-negative breast cancer.

A novel liquid biopsy for the detection of early-stage breast cancer has been granted a breakthrough device designation from the FDA.

The phase 2b AIPAC study, Eftilagimod alpha was found to improve overall survival in metastatic breast cancer along with a tolerable safety profile.

Elisa Agostinetto, MD, discusses the next steps in the research into the accuracy of PREDICT+ to predict survival in HER2-positive breast cancer.

Looking at 2 years' worth of data for patients with ERBB2-negative breast cancer, a study showed that the anti-inflammatory agent celecoxib had no disease free survival benefit.

Joseph A. Sparano, MD, who recently gave a talk during the 19th Annual School of Breast Oncology, discusses prolonging responses to therapy in patients with advanced breast cancer.

After showing significant improvement in survival, a breakthrough therapy designation application for leronlimab has been submitted to the FDA.

Florida Cancer Specialists & Research Institute, in collaboration with AdventHealth Heart of Florida and Central Florida Cancer Institute, has received a 3-year accreditation from the National Accreditation Program for Breast Centers.

After discovering the potential of a prophylactic breast cancer vaccine, Cleveland Clinic will be the site of a phase 1 clinical trial to test its safety.

Margaret E. Gatti-Mays, MD, MPH, FACP, evaluates the evolution of immunotherapy in cases of breast cancer for Breast Cancer Awareness Month.

The extended use of aromatase inhibitor therapy beyond 5 years remains controversial. However, a new study found that extending letrozole use significantly improves disease-free survival in postmenopausal patients with breast cancer.

Florida Cancer Specialists & Research Institute has received a three-year accreditation from the National Accreditation Program for Breast Centers.

Both the primary and key secondary end point of the phase 3 EMERALD study have been reached.

In an interview with Targeted Oncology, Evanthia Roussos Torres, MD, PhD, discussed the phase 1 investigation of the safety and efficacy of entinostat administered in combination with nivolumab and ipilimumab for the treatment of advanced HER2-negative breast cancer.

New findings from the phase 3 monarchE recently led to an FDA approval for abemaciclib. Joyce O’Shaughnessy, MD, presented the long-term analysis results during an ESMO Virtual Plenary.

In an interview with Targeted Oncology for Metastatic Breast Cancer Awareness Day, O’Regan discussed how the metastatic breast cancer landscape has changed and suggested potential regimens that could further that change.